BE Aerospace Inc.'s $500 Million Senior Unsecured Notes Rated 'BB'; Recovery Rating: '5' Mar 12

  • ID: 2085839
  • March 2012
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) March 8, 2012--Standard & Poor's Ratings Services today assigned its 'BB' issue-level rating to BE Aerospace Inc.'s planned $500 million senior unsecured notes maturing in 2022, one notch below the corporate credit rating. The recovery rating is '5', indicating our expectation that noteholders would receive modest (10%-30%) recovery in a payment default. We expect the U.S.-based aircraft supplier to use note proceeds toward repayment of borrowings under its revolving credit facility, which it drew to partially finance the $400 million acquisition of UFC Aerospace Corp. in January 2012. The corporate credit rating and outlook on BE Aerospace reflect our expectations that the company's earnings will increase, with a boost from acquired operations, and that commercial...

Companies mentioned in this report are: BE Aerospace Inc.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

BE Aerospace Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.